Drug intelligence / Profile preview

MEK-001

Development stage: Unknown
Lead developer: MEKanistic Therapeutics
Modality: Small Molecules

Overview

MEK-001 is a small molecule inhibitor developed by MEKanistic Therapeutics that targets the MAPK/ERK signaling pathway. It is specifically designed to treat tumors driven by the PIK3/mTOR pathway as well as those harboring KRAS, NRAS, or BRAF mutations. By inhibiting the MAPK/ERK cascade, MEK-001 aims to disrupt oncogenic signaling and tumor growth in patients with these specific genetic profiles. The program is currently in early-stage clinical development, with its development phase spanning from IND-enabling studies through Phase 2 trials.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on MEK-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEK-001.

Explore the full profile